medigraphic.com
ISSN 0016-3813 (Print)

2015, Number 2

<< Back Next >>

Gac Med Mex 2015; 151 (2)

Analysis of clinical-biological features of adult acute lymphoblastic leukemia

Díaz-Ruiz R, Aguilar-López L, Vega-Ruiz A, Garcés-Ruiz O, Nava-Zavala A, Rubio-Jurado B

Language: Spanish
References: 34
Page: 150-156
PDF size: 237.00 Kb.


ABSTRACT

Introducction: Acute lymphoblastic leukemia (ALL) is a clonal disease characterized by a proliferation of immature cells. In immunophenotypic, cytogenetic and molecular studies, it is a heterogeneous disease with diverse manifestations and prognoses. The treatment is complex and is associated with complications during its course. Patients and Methods: A prospective study of cohort of patients with ALL. Subjects were recruited consecutively from April 2010 to November 2012 in the Specialties Hospital, IMSS. Results: We included 29 patients with ALL; of 16 females (55%) and 13 males (45%), 18 (64%)were treated with modified BFM, seven (25%) HiperCVAD, and three (11%) others. In all, 70% achieved complete remission, and 8.5% partial responses. Induction mortality in five patients (17%). Consolidation mortality in three (13%). Relapse 33%, with a mean of eight months (5-16 months), overall survival five months. At 26 months of follow-up, 13 patients (45%) maintained RC. Disease-free survival of 10 months and overall survival of 12 months was observed. Conclusion: The majority of patients, regardless of risk, reach complete remission. We found that the clinical and biological characteristics showed no significant differences related to the outcome. Immunochemotherapy treatment may improve response.


REFERENCES

  1. Faderl S, O’Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116(5):1165-76.

  2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-43.

  3. Mejía Arangure, JM. Epidemiología de la leucemia aguda linfoblástica infantil. Revista de Hematología. 2010;11:35-6.

  4. Crespo Solís E. Epidemiología de las leucemias agudas. Revista de Hematología. 2010;11:37-9.

  5. Tirado-Gómez L, Mohar Betancourt A. Epidemiología de las neoplasias hemato-oncológicas. Cancerología. 2007;2:109-20.

  6. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.

  7. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.

  8. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535-48.

  9. Moorman AV, Harrison CJ, Buck GA, et al. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189-97.

  10. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced- intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366-74.

  11. Lassaletta Atienza A. Leucemias. Leucemia linfoblástica aguda. Pediatr Integral. 2004;VIII(5):435-42.

  12. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694): 269-71.

  13. Ramos C, Rozen E, León M, et al. [Results of treatment of acute lymphoblastic leukemia in two cohorts of Mexican patients]. Rev Med Chil. 2011;139(9):1135-42.

  14. Oriol A, Vives S, Hernández-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589-96.

  15. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 2003;101(10):3809-17.

  16. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20(10):2464-71.

  17. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-43.

  18. Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-41.

  19. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075-86.

  20. Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71(1):123-31.

  21. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8): 2025-37.

  22. Tang G, Zuo Z, Thomas DA, et al. Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica. 2012;97(6):919-25.

  23. Morris K, Weston H, Mollee P, Marlton P, Gill D, Kennedy G. Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population. Leuk Lymphoma. 2011;52(1):85-91.

  24. Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’stype adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17(8):2461-70.

  25. Usvasalo A, Räty R, Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica. 2008;93(8):1161-8.

  26. Cheson BD, Bennett JM, Kopecky KJ, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.

  27. Ruiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno JA, Montes-Montiel M, Ruiz- Argüelles GJ. Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience. Leuk Lymphoma. 2011;52(2):314-6.

  28. Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A, et al. [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007]. Rev Invest Clin. 2008;60(6):459-69.

  29. Thomas DA, O’Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113(25):6330-7.

  30. Maury S, Huguet F, Leguay T, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95(2):324-8.

  31. Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880-9.

  32. Reman O, Pigneux A, Huguet F, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res. 2008;32(11):1741-50.

  33. Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006;108(2):465-72.

  34. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010; 45(2):219-34.




2020     |     www.medigraphic.com